Competent Cells Market Size (2024 - 2029)

Competent Cells Market Analysis

The competent cells market is expected to register a CAGR of 9.4% over the forecast period.

The COVID-19 pandemic had a significant effect on the competent cells market. The increasing usage of competent cells in the research and development activities for the cell cloning activities of SARS-CoV-2. For example, an article published by Nature Journal in January 2021 reported the construction of a full-length SARS-CoV-2 genome via in-vitro competent cells in order to study the virus in-vitro and in vivo. Such application of competent cells in cloning the virus genome in order to develop appropriate treatments had a significant impact on the growth of the market. In addition, the demand for competent cells is expected to remain intact due to the emergence of a mutant strain of SARS-CoV-2 and to understand their mechanisms as well, thereby contributing to the growth of the market over the forecast period.

Advancements in molecular engineering due to the emergence of new cell technologies in biotechnology industries are augmenting the growth of the market studied. Additionally, increased investments from public and private companies and the development of advanced products are anticipated to boost the market growth in the studied regions. For example, in December 2021, Pfizer announced opening of a new state-of-the-art clinical manufacturing facility in Durham. The facility will expand Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy. Such increasing investment by various market players for the development of various advanced therapies is also expected to drive the demand for competent cells owing to the high efficacy in various biotechnology procedures, thereby contributing to the growth of the market.

According to an SEU article published in July 2022, venture capitalists in Europe invested nearly over USD 18 billion into European biotech startups. Such high amounts of capital-raising capabilities from major companies are likely to lead to further investment in research and development activities. They are also expected to drive the growth of the market over the forecast period.

However, the very high cost of research and development of competent cells and the market consolidation of a few major players are expected to hamper the market growth over the period.

Competent Cells Industry Segmentation

As per the scope of the report, competent cells are E.coli cells in which their cell walls are altered to allow easy incorporation of foreign DNA into the cells. Cells are made competent by either chemical or electrical means. Competent cells are used in cell transformation, cell cloning, and other cell engineering applications. The Competent Cells Market is segmented by Type (Chemically Competent Cells and Electrocompetent Cells), Application (Protein Expression, Cloning, Biotechnology, and Other Applications), End User (Biopharmaceutical Companies, Contract Research Organizations, and Academic Institutions), and Geography (North America, Asia-Pacific, Europe, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for all the above segments.